265 related articles for article (PubMed ID: 27604488)
1. Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.
Le X; Antony R; Razavi P; Treacy DJ; Luo F; Ghandi M; Castel P; Scaltriti M; Baselga J; Garraway LA
Cancer Discov; 2016 Oct; 6(10):1134-1147. PubMed ID: 27604488
[TBL] [Abstract][Full Text] [Related]
2. CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.
Stanland LJ; Ang HX; Hoj JP; Chu Y; Tan P; Wood KC; Luftig MA
Mol Cancer Res; 2023 Nov; 21(11):1148-1162. PubMed ID: 37493631
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Liu S; Tang Y; Yan M; Jiang W
Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
[TBL] [Abstract][Full Text] [Related]
4. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
5. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
[TBL] [Abstract][Full Text] [Related]
6. KDM6B Counteracts EZH2-Mediated Suppression of
Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
[TBL] [Abstract][Full Text] [Related]
7. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
8. Genomic Alterations in
Cai Y; Xu G; Wu F; Michelini F; Chan C; Qu X; Selenica P; Ladewig E; Castel P; Cheng Y; Zhao A; Jhaveri K; Toska E; Jimenez M; Jacquet A; Tran-Dien A; Andre F; Chandarlapaty S; Reis-Filho JS; Razavi P; Scaltriti M
Cancer Res; 2021 May; 81(9):2470-2480. PubMed ID: 33685991
[TBL] [Abstract][Full Text] [Related]
9. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
10. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer.
Xu YC; Wang X; Chen Y; Chen SM; Yang XY; Sun YM; Geng MY; Ding J; Meng LH
Theranostics; 2017; 7(4):974-986. PubMed ID: 28382169
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
12. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER
Ros S; Wright AJ; D'Santos P; Hu DE; Hesketh RL; Lubling Y; Georgopoulou D; Lerda G; Couturier DL; Razavi P; Pelossof R; Batra AS; Mannion E; Lewis DY; Martin A; Baird RD; Oliveira M; de Boo LW; Linn SC; Scaltriti M; Rueda OM; Bruna A; Caldas C; Brindle KM
Cancer Cell; 2020 Oct; 38(4):516-533.e9. PubMed ID: 32976773
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.
Song JH; Singh N; Luevano LA; Padi SKR; Okumura K; Olive V; Black SM; Warfel NA; Goodrich DW; Kraft AS
Mol Cancer Ther; 2018 Dec; 17(12):2710-2721. PubMed ID: 30190422
[TBL] [Abstract][Full Text] [Related]
16. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
17. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.
Costa C; Ebi H; Martini M; Beausoleil SA; Faber AC; Jakubik CT; Huang A; Wang Y; Nishtala M; Hall B; Rikova K; Zhao J; Hirsch E; Benes CH; Engelman JA
Cancer Cell; 2015 Jan; 27(1):97-108. PubMed ID: 25544637
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
